RNLX Description — Renalytix Plc
Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on supporting clinical management of kidney disease. KidneyIntelX, Co.'s diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems, to generate a patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to support the allocation of treatments and clinical resources to patients at highest risk.
|
Free RNLX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|